Hydrofluoric Acid & Lithium-Ion Battery

Hydrofluoric Acid Exposure from Lithium-Ion Battery Fires: Toxicology, Presentation, and Management

---

Clinical Overview and Mechanism

• Pathophysiology of Lithium-Ion Battery Fires:
  • Thermal runaway and combustion of lithium-ion batteries produce hydrofluoric acid (HF) vapor and other toxic fluorinated gaseous compounds.
  • The weak acid paradox: HF has a relatively low dissociation constant compared to strong mineral acids, remaining primarily in an un-ionized state.
  • Deep tissue penetration: The non-ionized HF molecule readily penetrates lipid-rich skin barriers and mucous membranes, diffusing deeply into subcutaneous tissues before full dissociation occurs.
  • Fluoride ion toxicity: Once dissociated, free fluoride ions avidly bind divalent cations, sequestering physiological calcium (Ca2+) and magnesium (Mg2+) to precipitate insoluble calcium fluoride (CaF2) and magnesium fluoride (MgF2).
  • Cellular destruction: Depletion of cellular calcium triggers cellular necrosis, liquefactive tissue destruction, and profound nerve stimulation.

Clinical Presentation and Hallmarks

• Hallmark Symptom:
  • Severe, throbbing pain that is distinctly out of proportion to the initial physical appearance of the burn or cutaneous exposure.
  • Due to delayed cellular injury, burns may initially appear as mild erythema or completely normal skin before progressing to deep, painful liquefaction necrosis.
• Mucosal and Inhalation Manifestations:
  • Inhalation of combustion fumes causes acute upper airway irritation, mucosal burning, rhinorrhea, cough, and stridor.
  • Lower respiratory tract injury can rapidly progress to chemical pneumonitis, bronchospasm, and non-cardiogenic pulmonary edema.
• Systemic Toxicology Risks:
  • Significant exposures lead to rapid systemic fluoride absorption.
  • Severe electrolyte derangements: profound hypocalcemia, refractory hypomagnesemia, and life-threatening hyperkalemia (triggered by fluoride-induced inhibition of sodium-potassium ATPase).
  • Cardiovascular collapse: QTc prolongation, intractable ventricular arrhythmias (ventricular fibrillation, torsades de pointes), and cardiac arrest.

Responder Safety and Decontamination Protocols

• Personal Protective Equipment (PPE):
  • Standard examination gloves (nitrile or latex) DO NOT provide adequate barrier protection against hydrofluoric acid penetration.
  • First responders and healthcare personnel must wear dedicated chemical-resistant gloves (heavy nitrile, butyl, or neoprene) and impervious gowns.
  • Appropriate respiratory protection (Self-Contained Breathing Apparatus [SCBA] in the field; acid-gas respirators in enclosed spaces) is mandatory during battery fire operations and initial patient handling to prevent secondary inhalation injury.
• Decontamination:
  • Immediate removal and bagging of all contaminated clothing and personal effects.
  • Copious irrigation of affected skin and eyes with water or physiological saline.

Medical Management and Antidotal Therapy

• Primary Antidote Principle:
  • Calcium administration neutralizes free fluoride ions by forming inert calcium fluoride complexes, arresting ongoing tissue destruction and correcting life-threatening electrolyte shifts.
• Cutaneous Exposure Treatment:
  • Topical Calcium Gluconate Gel: Apply 2.5% calcium gluconate gel generously to the exposed area, massaging it continuously into the skin until pain resolves.
  • Compounding alternative: If commercial gel is unavailable, mix 3.5 grams of calcium gluconate powder into 100 mL of water-soluble surgical lubricant, or mix 10 mL of 10% calcium gluconate with 30 mL of surgical lubricant.
• Inhalation Exposure Treatment:
  • Nebulized Calcium Gluconate: Administer nebulized 2.5% calcium gluconate solution promptly to neutralize inhaled acid fumes in the respiratory tree.
  • Preparation: Mix 1.5 mL of 10% calcium gluconate with 4.5 mL of sterile normal saline for nebulization.
  • Provide humidified supplemental oxygen and monitor for acute airway compromise.
• Systemic Toxicity and Resuscitation:
  • Continuous cardiac monitoring and baseline 12-lead ECG.
  • Urgent laboratory panel: serial ionized calcium, magnesium, potassium, and renal function.
  • Intravenous Calcium: Administer intravenous calcium gluconate (or calcium chloride via central venous access) to treat hypocalcemia and widen QTc intervals.
  • Magnesium Replenishment: Aggressively correct concurrent hypomagnesemia using intravenous magnesium sulfate.

High-Yield Lecture Takeaways

• Lithium-ion battery fires generate dangerous levels of hydrofluoric acid (HF) and fluorinated compounds.
• Suspect HF toxicity when a patient presents with excruciating pain out of proportion to burn appearance following battery fire smoke exposure.
• Standard medical gloves do not protect healthcare workers from HF; specialized chemical-resistant PPE and respiratory protection are mandatory.
• Calcium gluconate is the definitive antidote: use 2.5% topical gel for skin, nebulized 2.5% solution for inhalation, and intravenous calcium for systemic toxicity.
• Always monitor for sudden, fatal electrolyte shifts (hypocalcemia, hypomagnesemia, and hyperkalemia) that can precipitate malignant ventricular arrhythmias.

---

References

• Song C, Marano M, Lee R, Lee C, Ndubisi M, Elbahrawy M, Folarin A. 954 Hydrofluoric Acid Fumes Associated with Electric Vehicle Lithium Ion Battery Fires. Journal of Burn Care & Research. 2025;46(Supplement 1):S365. doi:10.1093/jbcr/iraf019.485
• Larsson F, Andersson P, Blomqvist P, et al. Toxic fluoride gas emissions from lithium-ion battery fires. Scientific Reports. 2017;7:10018. doi:10.1038/s41598-017-09784-z
• Keelan S, Murphy M, Abrahams M, Shelley O, Kennedy S. Hydrofluoric acid inhalation injury after electric bike battery fire. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2026;118:424-427. doi:10.1016/j.bjps.2026.04.035

LP in Low-Risk Febrile Infants

Lumbar Puncture in Low-Risk Febrile Infants Aged 0 to 28 Days: PECARN Criteria and Clinical Evidence

---

Clinical Case Presentation

• Patient Profile:
  • 23-day-old full-term infant boy presenting with a single measured rectal temperature of 38.2 degrees Celsius.
  • General status: Well-appearing, normal feeding patterns, vigorous tone, and normal alertness.
  • Associated symptoms: Rhinorrhea with multiple known viral upper respiratory sick contacts at home.
• Diagnostic Laboratory Findings:
  • Urinalysis: Negative (no pyuria, negative leukocyte esterase, negative nitrite).
  • Inflammatory markers: Normal (procalcitonin less than 0.5 ng/mL, normal C-reactive protein).
  • Complete blood count: Normal absolute neutrophil count (ANC less than 4,000/uL).
• Clinical Dilemma:
  • Does this well-appearing 23-day-old febrile neonate require an immediate lumbar puncture to rule out bacterial meningitis?

Core Clinical Recommendation

Routine lumbar puncture is not mandatory in this infant.

• Infants aged 0 to 28 days who meet all low-risk clinical and laboratory criteria can be safely managed without routine invasive cerebrospinal fluid testing.
• Individualized clinical assessment and shared decision-making with parents are strongly recommended.

The Updated PECARN Low-Risk Criteria (0 to 28 Days)

• Clinical Criteria:
  • Full-term gestation (at least 37 weeks).
  • Clinically well-appearing on physical examination (normal vital signs, perfusion, and neurological tone).
• Laboratory Thresholds:
  • Urinalysis: Negative for leukocyte esterase and nitrite; micro-urinalysis without pyuria.
  • Procalcitonin: Less than 0.5 ng/mL.
  • Absolute Neutrophil Count (ANC): Less than 4,000/uL.

Evidence and Diagnostic Performance

• Negative Predictive Value:
  • The updated PECARN rule demonstrates a 100% negative predictive value (NPV) for bacterial meningitis in infants meeting all low-risk criteria.
  • High sensitivity for identifying invasive bacterial infections (IBI), defined as bacteremia and bacterial meningitis.
• JAMA Meta-Analysis Evidence:
  • Supported by recent large-scale meta-analytic evidence published in JAMA Network.
  • Validates that low-risk stratification algorithms reliably identify neonates who do not harbor bacterial meningitis.
  • Helps prevent unnecessary hospitalizations, procedural complications, and exposure to empiric broad-spectrum parenteral antibiotics.

Clinical Risk-Benefit Considerations of Lumbar Puncture

• Risks of Routine Lumbar Puncture:
  • Traumatic taps occurring in 20% to 30% of neonatal procedures, confounding interpretation.
  • Increased likelihood of prolonged hospitalization and unnecessary intravenous antibiotic therapy while awaiting CSF cultures.
  • Procedural pain, transient hypoxemia, and caregiver anxiety.
• Protective Clinical Features in This Case:
  • Well-appearing state with a documented alternative viral focus (rhinorrhea and confirmed household sick contacts).
  • Reassuring laboratory profile confirming absence of systemic inflammatory cascade.

Practical Management and Discharge Safety Net

• Shared Decision-Making:
  • Engage parents in an open discussion regarding the extremely low baseline risk of meningitis versus procedural burdens.
  • Document informed shared decision-making in the electronic health record.
• Observation and Follow-Up Protocols:
  • Consider a brief period of emergency department observation to verify temperature stability and feeding adequacy.
  • Ensure guaranteed 24-hour outpatient pediatric re-evaluation.
  • Provide strict red flag return precautions: lethargy, poor oral intake, irritability, respiratory distress, or recurrent high fever.

Summary Lecture Takeaways

• Well-appearing febrile infants aged 0 to 28 days meeting all low-risk PECARN criteria do not routinely require lumbar puncture.
• Laboratory triaging (urinalysis, procalcitonin <0.5 ng/mL, ANC <4,000/uL) effectively rules out bacterial meningitis with 100% negative predictive value.
• Clinical judgment combined with shared parental decision-making optimizes outcomes by minimizing invasive procedures while preserving patient safety.

---

Reference: Pediatric Emergency Care Applied Research Network (PECARN) Clinical Prediction Rule; JAMA Network Meta-Analysis on Young Febrile Infant Evaluation.

Febrile Seizures and Antipyretics

Clinical Bottom Line

• These notes apply primarily to a neurologically healthy child who has returned to baseline after a simple febrile seizure.
• Simple febrile seizures usually have an excellent prognosis. Evaluation should focus on the cause of the fever and on excluding central nervous system infection when clinically indicated.
• Acetaminophen or ibuprofen may be used to relieve pain or distress. They should not be prescribed or scheduled with the promise that they will prevent a febrile seizure during a future febrile illness.
• A single open-label randomized trial found fewer recurrent seizures during the same fever episode with a specific rectal acetaminophen regimen. Important design and generalizability limitations prevent this result from supporting routine scheduled antipyretic prophylaxis at home.
• Routine long-term or intermittent antiseizure prophylaxis is not recommended after simple febrile seizures because treatment harms generally outweigh the limited clinical benefit of preventing a usually benign recurrence.

1. Definitions and Scope

• A febrile seizure is a seizure associated with fever in a young child without central nervous system infection, a major metabolic disturbance, or a prior afebrile seizure.
• The American Academy of Pediatrics (AAP) guideline population is 6 through 60 months of age.
• A simple febrile seizure has all of the following features:
  • Generalized onset
  • Duration shorter than 15 minutes
  • No recurrence within 24 hours
  • Complete clinical recovery without a persistent focal neurologic deficit
• A seizure is complex if it is focal, lasts 15 minutes or longer, or recurs within 24 hours.
• Children younger than 6 months, children outside the usual febrile-seizure age range, and children with an atypical course require reconsideration of the diagnosis and cause.
• These simple and complex labels describe seizure features. They do not replace assessment for meningitis, encephalitis, toxic or metabolic causes, trauma, epilepsy, or other serious illness.

2. Initial Emergency Department Priorities

• During an active seizure:
  • Protect the airway and assess breathing and circulation.
  • Place the child in a safe lateral position when practical.
  • Remove nearby hazards.
  • Do not restrain the child and do not place anything in the mouth.
  • Record the seizure duration and observed focal features.
  • Treat a prolonged ongoing seizure according to the local pediatric seizure protocol.
• After the seizure stops:
  • Confirm recovery toward the neurologic baseline.
  • Look for the source of fever.
  • Assess for meningitis, encephalitis, sepsis, toxic exposure, hypoglycemia, electrolyte disturbance, trauma, and other alternative diagnoses when suggested by the history or examination.

3. Diagnostic Testing After a Simple Febrile Seizure

• A well-appearing child who has returned to baseline after a simple febrile seizure generally does not need tests solely because the seizure occurred.
• Routine electroencephalography, blood testing, computed tomography, and magnetic resonance imaging are not indicated for an otherwise typical simple febrile seizure.
• Testing should instead be driven by the suspected cause of fever and by specific clinical abnormalities.
• Lumbar puncture should be performed when signs or symptoms raise concern for meningitis.
• The 2011 AAP guideline states that lumbar puncture is an option for a child 6 to 12 months of age with incomplete or unknown Haemophilus influenzae type b or pneumococcal immunization, and for a child pretreated with antibiotics that may mask meningitis.
• The AAP documents from 2008 and 2011 are historical guidelines with automatic expiration language. Their major conclusions remain consistent with current NICE guidance, the 2023 Japanese Society of Child Neurology guideline, and a 2024 AAP policy statement that routine neuroimaging is unnecessary after a simple febrile seizure.

4. Prognosis and Recurrence Counseling

• Febrile seizures occur in approximately 2% to 5% of children in the usual age range.
• Nearly all neurologically healthy children with simple febrile seizures have an excellent outcome.
• Historical AAP estimates suggest recurrence in approximately:
  • 50% of children whose first febrile seizure occurs before 12 months of age
  • 30% of children whose first febrile seizure occurs after 12 months of age
  • 50% of children who have already had a second febrile seizure
• A simple febrile seizure is not the same as epilepsy.
• The subsequent epilepsy risk is low after a simple febrile seizure, although estimates vary with follow-up duration and patient characteristics.
• Risk is higher when complex features, preexisting neurodevelopmental abnormalities, or a family history of epilepsy are present.
• No evidence shows that preventing recurrent simple febrile seizures prevents later epilepsy or improves cognition, school performance, behavior, or survival.

5. What Antipyretics Can and Cannot Do

• Appropriate purpose:
  • Reduce pain, discomfort, or distress associated with fever.
• Inappropriate promise:
  • Prevent a febrile seizure during a future febrile illness.
• NICE guidance states that antipyretics do not prevent febrile convulsions and should not be used specifically for that purpose.
• The 2023 Japanese Society of Child Neurology guideline similarly recommends against antipyretics for prevention of recurrence during a later febrile illness. It permits their usual use to relieve discomfort.
• Families should not be instructed to wake a comfortable sleeping child solely to administer an antipyretic on a fixed schedule for seizure prevention.
• Antipyretic selection and dosing should follow the child's weight, age, contraindications, product instructions, and local prescribing guidance. Avoid duplicate acetaminophen-containing products and dosing errors.

6. Evidence Across Separate Febrile Illnesses

• Randomized trials of acetaminophen, ibuprofen, or diclofenac-based regimens have not demonstrated prevention of recurrent febrile seizures during later febrile illnesses.
• A 2021 Cochrane review included 32 randomized or quasi-randomized trials involving 4,431 children across prophylactic interventions.
• For intermittent ibuprofen compared with placebo, no significant recurrence reduction was found at 6, 12, or 24 months.
• A 2021 systematic review and meta-analysis reported no evidence of benefit for antipyretic prophylaxis during distant fever episodes. Its pooled estimate from 2 randomized trials was an odds ratio of 0.92 (95% confidence interval 0.57 to 1.48).
• This evidence supports a clear counseling statement: treating discomfort is reasonable, but fever control cannot be relied upon to prevent the next febrile seizure.

7. Evidence During the Same Fever Episode

Murata et al, 2018

• Design:
  • Single-center, prospective, open-label randomized trial in Japan
  • Children 6 to 60 months of age presenting after a febrile seizure
  • 423 children analyzed: 219 in the acetaminophen group and 204 in the control group
• Intervention:
  • Rectal acetaminophen 10 mg/kg on arrival, then every 6 hours when temperature remained above 38.0 degrees C
  • Continued until 24 hours after the first seizure
  • The control group received no antipyretic and no placebo during that interval
• Result:
  • Same-episode seizure recurrence occurred in 9.1% of the acetaminophen group and 23.5% of controls
  • Absolute risk reduction was 14.4 percentage points
  • The approximate number needed to treat was 7, calculated from the reported event rates
• Major limitations:
  • Single center
  • Open label
  • No placebo control
  • Rectal regimen rather than usual oral home treatment
  • Substantial exclusions, including children who had already received rectal diazepam and children with diarrhea
  • Randomized participants were excluded from the final analysis, so the analysis was not a complete intention-to-treat analysis
  • The control condition of no antipyretic may not represent routine practice
• Interpretation:
  • The trial suggests a possible reduction in another seizure within the same fever episode under a specific monitored regimen.
  • It does not show that routine oral antipyretics prevent seizures during later illnesses.
  • It does not justify promising seizure prevention or automatically prescribing scheduled home antipyretics after every simple febrile seizure.
  • The 2023 Japanese guideline reviewed this finding but still did not recommend antipyretics for prevention of same-episode recurrence.

8. Antiseizure Prophylaxis

• Intermittent diazepam and continuous phenobarbital can reduce recurrence in some trials.
• Adverse effects are common and may include sedation, ataxia, irritability, and impaired assessment of a child with evolving central nervous system infection.
• Because recurrent simple febrile seizures are usually benign, the AAP and Cochrane review conclude that routine continuous or intermittent antiseizure prophylaxis is not justified for most children.
• Acute rescue medication for an ongoing prolonged seizure is a separate indication and should follow an individualized emergency plan.
• Atypical, prolonged, focal, or recurrent events and cases involving substantial family anxiety may warrant follow-up with pediatrics or pediatric neurology.

9. Caregiver First-Aid Script

• Place the child on the side on a safe surface.
• Move hard or sharp objects away.
• Do not hold the child down.
• Do not place a spoon, finger, medication, or other object in the mouth.
• Time the seizure and observe whether movements are generalized or focal.
• Call emergency medical services immediately if the seizure continues, breathing is abnormal, cyanosis develops, serious illness is suspected, or the child does not progressively recover after the seizure.
• Seek repeat clinical assessment for another seizure in the same 24-hour period, an atypical event, or a child outside the usual age range.
• Follow the local institution's approved seizure and emergency-call instructions. A fixed time threshold should not delay help when breathing or recovery is abnormal.

10. Suggested Family Explanation

Your child has returned to normal and today's event fits a simple febrile seizure. These seizures are common in young children and usually have an excellent outcome. Another seizure may occur during this illness or with a later fever, but this does not mean your child has epilepsy. Acetaminophen or ibuprofen can be used when your child is uncomfortable, but they cannot reliably prevent another febrile seizure. If another seizure occurs, place your child on the side, do not put anything in the mouth, and time the event. Call emergency services if the seizure continues, breathing is abnormal, the lips turn blue, or recovery does not progress normally.

11. Key Teaching Distinction

• Future febrile illnesses: antipyretics do not prevent recurrent febrile seizures.
• Same fever episode: one limited trial suggests possible benefit from a specific rectal acetaminophen regimen, but the evidence is insufficient for routine prophylaxis.
• Routine practice: use antipyretics for comfort, not as seizure-prevention therapy.

---

References

1. Hou EM. Pediatric febrile seizures: caregiver education and evidence for antipyretic prevention. 2026. https://hou-em.netlify.app/febrile-seizure-antipyretics/
2. American Academy of Pediatrics, Subcommittee on Febrile Seizures. Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures. Pediatrics. 2008;121(6):1281-1286. doi:10.1542/peds.2008-0939.
3. American Academy of Pediatrics, Subcommittee on Febrile Seizures. Febrile seizures: guideline for the neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics. 2011;127(2):389-394. doi:10.1542/peds.2010-3318.
4. American Academy of Pediatrics. Optimizing advanced imaging of the pediatric patient in the emergency department: policy statement. Pediatrics. 2024;154(1):e2024066854. AAP policy statement.
5. National Institute for Health and Care Excellence. Fever in under 5s: assessment and initial management. NG143. Recommendation 1.6.1. NICE recommendations.
6. Japanese Society of Child Neurology. Clinical practice guideline for febrile seizures 2023. Section 6, CQ6-1. Guideline PDF.
7. Offringa M, Newton R, Nevitt SJ, Vraka K. Prophylactic drug management for febrile seizures in children. Cochrane Database Syst Rev. 2021;6:CD003031. doi:10.1002/14651858.CD003031.pub4.
8. Murata S, Okasora K, Tanabe T, et al. Acetaminophen and febrile seizure recurrences during the same fever episode. Pediatrics. 2018;142(5):e20181009. doi:10.1542/peds.2018-1009.
9. Hashimoto R, Suto M, Tsuji M, et al. Use of antipyretics for preventing febrile seizure recurrence in children: a systematic review and meta-analysis. Eur J Pediatr. 2021;180(4):987-997. doi:10.1007/s00431-020-03845-8.

---

Clinical education note for health professionals. This document is not a substitute for current institutional protocols or patient-specific medical judgment.

Preexcited Atrial Fibrillation

Definition and Mechanism

• Preexcited atrial fibrillation (AF) occurs when atrial impulses reach the ventricles through an antegrade-conducting accessory pathway, such as a bundle of Kent.
• The accessory pathway bypasses the normal filtering function of the atrioventricular (AV) node.
• Rapid, irregular ventricular activation can deteriorate into ventricular fibrillation (VF) and sudden cardiac death.

ECG Recognition

• Suspect preexcited AF when the rhythm is:
  • Irregularly irregular
  • Very rapid (fastest may >250~300/min)
  • Wide complex
  • Variable in QRS width and morphology from beat to beat
• A shortest preexcited R-R interval of less than 250 ms suggests a rapidly conducting pathway and increased risk of VF.
• A delta wave may be visible during sinus rhythm but may not be obvious during the acute tachyarrhythmia.

Immediate Management

• Assess hemodynamic stability immediately.
• If unstable:
  • Perform immediate synchronized electrical cardioversion.
• If stable:
  • Use intravenous procainamide or intravenous ibutilide for pharmacologic cardioversion.
  • Maintain continuous cardiac and blood pressure monitoring.
  • Prepare for synchronized cardioversion if the patient deteriorates or drug therapy fails.

Drugs to Avoid

• Do not administer AV nodal blocking drugs because AV nodal slowing can shift conduction toward the accessory pathway, accelerate the ventricular response, and precipitate VF.
• Contraindicated agents include:
  • Adenosine
  • Beta blockers
  • Diltiazem
  • Verapamil
  • Digoxin
  • Amiodarone
• A common error is treating this rhythm as ordinary AF with rapid ventricular response.

Diagnostic and Treatment Pearls

• An irregular wide-complex tachycardia should trigger consideration of preexcited AF.
• When the diagnosis is uncertain, avoid empiric AV nodal blockade until preexcitation has been excluded.
• Do not rely on ventricular rate control alone. The acute goal is restoration of sinus rhythm without accelerating accessory-pathway conduction.
• After stabilization, obtain cardiology or electrophysiology consultation. Catheter ablation of the accessory pathway is recommended to prevent recurrent preexcited AF and reduce the risk of VF.

Summary Takeaway

• Preexcited AF is a potentially lethal, very rapid, irregular wide-complex tachyarrhythmia.
• Unstable patient: immediate synchronized cardioversion.
• Stable patient: intravenous procainamide or ibutilide.
• Never use AV nodal blockers.

---

Reference

Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Circulation. 2024;149:e1-e156. https://doi.org/10.1161/CIR.0000000000001193

Oseltamivir Prophylaxis of Influenza

Oseltamivir Prophylaxis and Breakthrough Influenza

Scope

• These standard adult and adolescent regimens apply to patients aged 13 years or older with normal renal function.
• Adjust the dose for renal impairment and verify age-specific or weight-based dosing in younger patients.
• This is a teaching note, not patient-specific prescribing guidance.

The Core Dosing Distinction

• Oseltamivir prophylaxis is not given as half of the treatment dose at the same frequency.
• The dose per administration is the same, but the frequency differs:
  • Prophylaxis: 75 mg orally once daily.
  • Treatment: 75 mg orally twice daily for 5 days.
• The total daily prophylactic dose is therefore 75 mg, compared with 150 mg for treatment.
• Practical interpretation: Prophylaxis provides half the treatment total daily dose by halving the dosing frequency, not by halving each 75 mg dose.

Post-Exposure Prophylaxis

• Start as soon as possible, ideally within 48 hours after close contact with a person who has influenza.
• The current US product labeling recommends 75 mg orally once daily for at least 10 days after close contact.
• Current CDC clinical guidance uses 7 days after the last known exposure for routine chemoprophylaxis.
• The apparent difference reflects a product-label regimen versus current public health guidance. Follow the applicable local guideline, exposure pattern, and institutional policy.

Prophylaxis During a Community Outbreak

• Standard adult and adolescent regimen: 75 mg orally once daily.
• Product labeling permits prophylaxis for up to 6 weeks during a community outbreak.
• In immunocompromised patients, prophylaxis may be continued for up to 12 weeks.
• Protection lasts only while dosing continues.
• Longer prophylaxis requires reassessment of ongoing exposure, renal function, tolerance, and the current susceptibility of circulating influenza viruses.

If Influenza Symptoms Develop During Prophylaxis

• Do not continue once-daily prophylaxis as if it were adequate treatment.
• Promptly reassess for suspected or confirmed influenza and switch to a treatment regimen.
• For uncomplicated influenza in an adult or adolescent with normal renal function, the standard regimen is 75 mg orally twice daily for 5 days.
• Prior prophylaxis days do not constitute treatment days. Begin the treatment course when treatment dosing starts.
• Start treatment as soon as possible. Benefit is greatest when treatment begins within 48 hours of symptom onset, but treatment should not be withheld solely because 48 hours have passed in hospitalized patients or those with severe, progressive, or high-risk illness.
• IDSA guidance recommends considering an antiviral with a different resistance profile, when appropriate and not contraindicated, because breakthrough influenza during chemoprophylaxis can raise concern for antiviral resistance.

Evidence for Post-Exposure Prophylaxis

• A 2024 WHO-funded systematic review and network meta-analysis included 33 randomized trials involving 19,096 participants.
• When started promptly after exposure, oseltamivir probably reduced symptomatic seasonal influenza in people at high risk for severe disease:
  • Risk ratio: 0.40.
  • 95% confidence interval: 0.26 to 0.62.
  • Certainty of evidence: moderate.
• In people at low risk for severe disease, oseltamivir probably did not provide an important reduction in symptomatic influenza.
• The review did not establish an important reduction in hospitalization or all-cause mortality from oseltamivir post-exposure prophylaxis.
• Randomized evidence remains limited for several special populations, including pregnant patients, infants younger than 1 year, and patients with renal impairment. These patients require population-specific guidance rather than automatic use of the standard adult regimen.

Clinical Pearls

• Think in terms of frequency, not a smaller capsule: 75 mg once daily for prophylaxis versus 75 mg twice daily for treatment.
• Anchor prophylaxis duration to the type and timing of exposure.
• New symptoms during prophylaxis trigger clinical reassessment and treatment dosing.
• Renal impairment changes both treatment and prophylaxis dosing.
• Chemoprophylaxis is an adjunct to vaccination and infection-control measures, not a substitute for them.

Take-Home Summary

• For adults and adolescents aged 13 years or older with normal renal function, oseltamivir prophylaxis and treatment use the same 75 mg dose per administration.
• Prophylaxis is once daily, while treatment is twice daily for 5 days.
• FDA labeling recommends at least 10 days after close contact and up to 6 weeks during a community outbreak, with continuation up to 12 weeks in immunocompromised patients.
• CDC duration guidance may differ, including 7 days after the last known exposure.
• If influenza develops during prophylaxis, switch from prophylaxis to a full treatment regimen and consider the possibility of antiviral resistance.

---

References

• DailyMed. Oseltamivir phosphate capsules, prescribing information. Updated January 28, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dac3ba2-b667-4081-9395-8db45d38ceac
• US Centers for Disease Control and Prevention. Influenza Antiviral Medications: Summary for Clinicians. Updated March 10, 2026. https://www.cdc.gov/flu/hcp/antivirals/summary-clinicians.html
• Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update for the Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Clinical Infectious Diseases. 2019;68(6):e1-e47. https://www.idsociety.org/practice-guideline/influenza/
• Zhao Y, Gao Y, Guyatt G, et al. Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis. Lancet. 2024;404(10454):764-772. doi:10.1016/S0140-6736(24)01357-6. https://pubmed.ncbi.nlm.nih.gov/39181596/

Prepared as an educational lecture note. Verify current local guidance and patient-specific dosing before prescribing.